{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"31.43","upperLimit":"41.40","value":"33.30"},{"groupId":"OG001","lowerLimit":"22.10","upperLimit":"46.83","value":"35.4"},{"groupId":"OG002","lowerLimit":"25.75","upperLimit":"50.45","value":"38.20"},{"groupId":"OG003","lowerLimit":"18.05","upperLimit":"36.93","value":"22.50"},{"groupId":"OG004","lowerLimit":"25.73","upperLimit":"42.65","value":"34.25"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"6"},{"groupId":"OG004","value":"41"}],"units":"Participants"}],"title":"Baseline CD14+ monocytes among viable cells"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"29.45","upperLimit":"34.18","value":"31.50"},{"groupId":"OG001","lowerLimit":"28.40","upperLimit":"40.45","value":"34.95"},{"comment":"There was only 1 sample.","groupId":"OG002","lowerLimit":"NA","upperLimit":"NA","value":"23.70"},{"groupId":"OG003","lowerLimit":"25.83","upperLimit":"46.20","value":"33.25"},{"groupId":"OG004","lowerLimit":"27.80","upperLimit":"47.85","value":"32.75"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"6"},{"groupId":"OG004","value":"41"}],"units":"Participants"}],"title":"Post-Treatment CD14+ monocytes among viable cells"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.66","upperLimit":"5.04","value":"3.19"},{"groupId":"OG001","lowerLimit":"2.66","upperLimit":"4.18","value":"3.80"},{"groupId":"OG002","lowerLimit":"2.58","upperLimit":"4.44","value":"3.32"},{"groupId":"OG003","lowerLimit":"3.14","upperLimit":"4.30","value":"3.92"},{"groupId":"OG004","lowerLimit":"1.95","upperLimit":"5.65","value":"3.50"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"6"},{"groupId":"OG004","value":"41"}],"units":"Participants"}],"title":"Baseline regulatory T cells among CD4+ T cells"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.78","upperLimit":"3.04","value":"1.87"},{"groupId":"OG001","lowerLimit":"4.17","upperLimit":"5.50","value":"4.42"},{"comment":"There was only 1 sample.","groupId":"OG002","lowerLimit":"NA","upperLimit":"NA","value":"1.79"},{"groupId":"OG003","lowerLimit":"2.44","upperLimit":"3.20","value":"3.11"},{"groupId":"OG004","lowerLimit":"1.68","upperLimit":"3.37","value":"2.53"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"6"},{"groupId":"OG004","value":"41"}],"units":"Participants"}],"title":"Post-Treatment regulatory T cells among CD4+ T cells"}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"6"},{"groupId":"OG004","value":"41"}],"units":"Participants"}],"description":"Blood samples were collected via venipuncture and immunophenotyping of PBMCs were performed by multiparameter flow cytometry for CD14+ monocytes among viable cells, and regulatory T cells among CD4+ T cells.","dispersionType":"Inter-Quartile Range","groups":[{"description":"Phase I Dose Level (DL) 1 Topotecan 1mg/m\\^2 intravenous (IV) (days 1-5); VX970 (M6620) 140mg/m\\^2 IV on day 5","id":"OG000","title":"Phase I DL1 Topotecan 1mg/m^2 Intravenous (IV) (Days 1-5); VX970 (M6620) 140mg/m^2 IV on Day 5"},{"description":"Phase I Dose Level (DL) 2 Topotecan 1mg/m\\^2 intravenous (IV) (days 1-5); VX970 (M6620) 140mg/m\\^2 IV on day 2, 5","id":"OG001","title":"Phase I DL2 Topotecan 1mg/m^2 Intravenous (IV) (Days 1-5); VX970 (M6620) 140mg/m^2 IV on Day 2, 5"},{"description":"Phase I Dose Level (DL) 3 Topotecan 1.25mg/m\\^2 intravenous (IV) (days 1-5); VX970 (M6620) 140mg/m\\^2 IV on day 2, 5","id":"OG002","title":"Phase I DL3 Topotecan 1.25mg/m^2 Intravenous(IV) (Days 1-5); VX970 (M6620) 140mg/m^2 IV on Day 2, 5"},{"description":"Phase I Dose Level (DL) 4 Topotecan 1.25mg/m\\^2 intravenous (IV) (days 1-5); VX970 (M6620) 210mg/m\\^2 IV on day 2, 5","id":"OG003","title":"Phase I DL4 Topotecan 1.25mg/m^2 Intravenous(IV) (Days 1-5); VX970 (M6620) 210mg/m^2 IV on Day 2, 5"},{"description":"Phase II Dose Level (DL) 4 Topotecan 1.25mg/m\\^2 intravenous (IV) (days 1-5); VX970 (M6620) 210mg/m\\^2 IV on day 2, 5.\n\nMaximum Tolerated Dose/Recommended Phase II Dose.\n\nSmall cell lung cancer (SCLC) participants only.","id":"OG004","title":"Phase II Dose Level (DL) 4 Topotecan 1.25mg/m^2; VX970 (M6620) 210mg/m^2 Recommended Phase II Dose"}],"paramType":"MEDIAN","populationDescription":"Only one participant had a post treatment sample in phase 1 DL3.","reportingStatus":"POSTED","timeFrame":"Baseline and 3 weeks post-treatment","title":"Percentage of Peripheral Blood Mononuclear Cells (PBMCs): Cluster of Differentiation 14 (CD14)+ Monocytes Among Viable Cells, and Regulatory T Cells Among Cluster of Differentiation 4 (CD4)+ T Cells At Baseline and Post-Treatment","type":"SECONDARY","unitOfMeasure":"percentage of PBMCs"}